EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Ultra-Hypofractionated Whole-Breast Irradiation: Real-World Data From a Prospective Single-Institution Cohort

Olga Unterkirhere, Tino Streller, David Jeller, Philippe Logaritsch, Maja Arnold, Susanne Bucher, Peter Dubsky, Christoph Glanzmann, Gabriela Studer

Clinical Breast Cancer · 2026

DOI: 10.1016/j.clbc.2026.08.018 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Breast Cancer, 2026. Verfasst von Olga Unterkirhere und 8 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Oncology Department, Kantonsspital Luzern, Luzern, Switzerland. Electronic address: olga.unterkirhere@luks.ch. Hauptthemen laut MEDLINE: Breast Neoplasms, Radiation Dose Hypofractionation, Neoplasm Recurrence, Local. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Ultra-hypofractionated (5-fraction) adjuvant whole-breast irradiation (WBI) is effective for early-stage breast cancer, as demonstrated by the FAST-Forward. We implemented a risk-adapted program, including 28 Gy/5-fractions when a boost was indicated but infeasible, and report real-world tolerability and early outcomes of this approach in a prospective cohort. PATIENTS AND METHODS: This prospective single-institution observational study included 718 patients with stage 0 to IIIA breast cancer treated after breast-conserving surgery (2020-2024). Patients received 26 Gy in 5 daily fractions (with or without a moderately hypofractionated sequential boost of 10-12.5 Gy in 4-5 fractions) or 28 Gy in 5 twice-weekly fractions (instead of a boost, n = 201). Acute and late toxicity, patient-reported outcomes, and cosmesis were prospectively assessed at regular follow-up visits. RESULTS: No grade ≥3 acute toxicities occurred; 13% developed grade 2 acute skin reactions. At 27 months median follow-up, late toxicity was low: 11% of patients had any grade ≥2 late effect (3% grade 3). The 3-year cumulative incidence of ipsilateral in-breast recurrence was 0.6%, and 3-year overall survival was 98.5%. Exploratory comparisons detected no significant toxicity differences among regimens. Larger breast volume was associated with acute and late toxicity. Cosmesis was good or excellent in 98% of patients. CONCLUSION: Risk-adapted 5-fraction WBI was well tolerated with excellent early tumor control. A 28 Gy twice-weekly regimen shortened treatment when a boost was infeasible without compromising early-to-intermediate outcomes. These findings support routine adoption of ultra-hypofractionated adjuvant radiotherapy in early breast cancer, pending long-term follow-up for safety confirmation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsRadiation Dose HypofractionationNeoplasm Recurrence, LocalHumansFemaleProspective StudiesMiddle AgedRadiotherapy, AdjuvantMastectomy, SegmentalAgedAdultFollow-Up StudiesNeoplasm StagingAged, 80 and over

Stichwörter der Autor:innen

Accelerated WBIAdjuvant WBICosmetic outcomeRadiotherapyToxicity

Autor:innen und Institutionen

  • Radiation Oncology Department, Kantonsspital Luzern, Luzern, Switzerland. Electronic address: olga.unterkirhere@luks.ch.
  • Radiation Oncology Department, Kantonsspital Luzern, Luzern, Switzerland.
  • School of Medicine, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
  • Breast Center, Kantonsspital Luzern, Luzern, Switzerland.
  • Faculty of Health Sciences and Medicine, University of Lucerne, Luzern, Switzerland; Tumour- and Breast Cancer Centre, Hirslanden Klinik St. Anna, Lucerne, Switzerland.
  • Radiation Oncology Department, Kantonsspital Luzern, Luzern, Switzerland; Faculty of Health Sciences and Medicine, University of Lucerne, Luzern, Switzerland.

Zitieren

APA

Unterkirhere, O., Streller, T., Jeller, D., Logaritsch, P., Arnold, M., Bucher, S., Dubsky, P., Glanzmann, C., & Studer, G. (2026). Ultra-Hypofractionated Whole-Breast Irradiation: Real-World Data From a Prospective Single-Institution Cohort. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2026.08.018

Vancouver

Unterkirhere O, Streller T, Jeller D, Logaritsch P, Arnold M, Bucher S, et al. Ultra-Hypofractionated Whole-Breast Irradiation: Real-World Data From a Prospective Single-Institution Cohort. Clinical Breast Cancer. 2026. doi:10.1016/j.clbc.2026.08.018

BibTeX
@article{Unterkirhere2026,
  author = {Unterkirhere, Olga and Streller, Tino and Jeller, David and Logaritsch, Philippe and Arnold, Maja and Bucher, Susanne and Dubsky, Peter and Glanzmann, Christoph and Studer, Gabriela},
  title = {Ultra-Hypofractionated Whole-Breast Irradiation: Real-World Data From a Prospective Single-Institution Cohort},
  journal = {Clinical Breast Cancer},
  year = {2026},
  doi = {10.1016/j.clbc.2026.08.018}
}
Kostenlos starten →